{"title":"PERBANDINGAN RESPON AWAL PEMBERIAN WARFARIN PADA PASIEN OBESITAS DAN NON OBESITAS DI RSUP DR. SARDJITO YOGYAKARTA","authors":"D. Oktianti, S. I Dewa Putu Pramantara S.","doi":"10.22146/JMPF.366","DOIUrl":null,"url":null,"abstract":"Warfarin oral anticoagulant is most prescribed in the world. Warfarin is\nprescribed for prevention of thromboembolic event, associated with atrial\nfibrillation, prosthetic heart valves, or history of vascular thrombosis. Variability\nin warfarin dose because of the variation among the patient and therapeutic\nresponse depend on age, influence of another disease, nutritional status, weight,\nconcomitant medicine, influence of genetic polymorphism of the CYP2C9 or\nVKORC1. Optimal dose warfarin can be monitored with international normalized\nratio (INR). The aims of this study is to compare initial warfarin response between\nobese and non obese patient at RSUP dr. Sardjito Yogyakarta.\nThis study was a retrospective with design descriptive observational study.\nSubject in research is outpatient that receive newly warfarin therapy and with\ncomplete INR value. To determine time required to achieve a therapeutic INR was\nanalyzed using non parametric test with Kaplan-Meier method.\nThe result of this study, 92 patient were included. Patient distribution were 44\npatient with obesity and 48 patient with normal weight. Based on Kaplan-Meier\nanalyzed the median time to achieve therapeutic INR in obese patient is 56 days\nand in normal weight is 57 days with p=0,316 (p>0,05) there is no significant\ndifference between the group.\nKey word: Warfarin, Obese, non obese, INR, time to achieve therapeutic INR","PeriodicalId":125871,"journal":{"name":"Journal of Management and Pharmacy Practice","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Management and Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22146/JMPF.366","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Warfarin oral anticoagulant is most prescribed in the world. Warfarin is
prescribed for prevention of thromboembolic event, associated with atrial
fibrillation, prosthetic heart valves, or history of vascular thrombosis. Variability
in warfarin dose because of the variation among the patient and therapeutic
response depend on age, influence of another disease, nutritional status, weight,
concomitant medicine, influence of genetic polymorphism of the CYP2C9 or
VKORC1. Optimal dose warfarin can be monitored with international normalized
ratio (INR). The aims of this study is to compare initial warfarin response between
obese and non obese patient at RSUP dr. Sardjito Yogyakarta.
This study was a retrospective with design descriptive observational study.
Subject in research is outpatient that receive newly warfarin therapy and with
complete INR value. To determine time required to achieve a therapeutic INR was
analyzed using non parametric test with Kaplan-Meier method.
The result of this study, 92 patient were included. Patient distribution were 44
patient with obesity and 48 patient with normal weight. Based on Kaplan-Meier
analyzed the median time to achieve therapeutic INR in obese patient is 56 days
and in normal weight is 57 days with p=0,316 (p>0,05) there is no significant
difference between the group.
Key word: Warfarin, Obese, non obese, INR, time to achieve therapeutic INR